Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2201 - 2225 of 15149 in total
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and...
Approved
Matched Description: … LABAs including improved convenience and compliance and improved airflow over a 24-hour period. ... novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and ... signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and
Matched Categories: … olodaterol and tiotropium bromide …
Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections.[L13880,L13883] It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK...
Approved
Investigational
Matched Iupac: … methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-2-yl]formamido}methyl)amino]-2-aminohexanoic acid
Matched Description: … Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and ... has been proven a cost-effective alternative to treatment with [minocycline] with comparable safety and ... It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. …
An opioid antagonist with properties similar to those of naloxone; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia,...
Approved
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers...
Approved
Matched Description: … treatment for these types of cancers as patients generally have better survival, side effect profiles, and
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Hormone Antagonists and Related Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Coumarin derivative that acts as a long-acting oral anticoagulant.
Approved
Investigational
Matched Categories: … Blood and Blood Forming Organs …
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Approved
Matched Description: … The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances …
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Approved
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors...
Approved
Investigational
Matched Description: … that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and ... [L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. ... In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and
Matched Categories: … tamsulosin and tadalafil ... macitentan and tadalafil ... ambrisentan and tadalafil ... finasteride and tadalafil ... Genito Urinary System and Sex Hormones …
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.[L45698,A258488] Glofitamab was approved...
Approved
Investigational
Matched Description: … It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting ... antigens found on B- and T-cells, respectively. ... Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Approved
Investigational
Withdrawn
Matched Description: … The FDA issued a warning letter regarding this risk to health care professionals and patients. …
Matched Categories: … Alimentary Tract and Metabolism ... Benzamides and benzamide derivatives …
Lifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient which undergo isolation, ex vivo expansion, and activation Lifileucel was granted accelerated approval by the FDA on February 16, 2024, for the treatment of unresectable or metastatic melanoma.
Approved
Investigational
Matched Description: … suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …
Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta...
Approved
Investigational
Matched Description: … Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and ... appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and ... ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and
Matched Categories: … Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Approved
Experimental
Matched Categories: … Biguanides and Amidines ... Antiseptics and Disinfectants ... Ophthalmological and Otological Preparations …
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in...
Approved
Investigational
Matched Description: … D2 and D3 receptors. ... , and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major ... Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine …
Matched Categories: … Benzamides and benzamide derivatives …
Cyclopenthiazide is a thiazide diuretic with antihypertensive properties. In a double blind, randomized crossover study, cyclopenthiazide was effective in reducing diastolic blood pressure in mildly hypertensive non-insulin dependent diabetic patients . It is a positive allosteric modulator at AMPA-A receptors .
Approved
Matched Categories: … cyclopenthiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... cyclopenthiazide and potassium-sparing agents ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option. It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. It was never approved by the FDA.
Approved
Withdrawn
Matched Description: … [A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing …
Matched Categories: … medrogestone and estrogen ... Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Progestogens and Estrogens, Sequential Preparations …
Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …
Clotiazepam is a thienodiazepine, not approved for sale in the U.S. or Canada, but has been approved in the U.K. It is a schedule IV drug in Canada.
Approved
Illicit
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.
Approved
Matched Iupac: … 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Siponimod, also known as Mayzent, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a sphingosine-1-phosphate (S1P) receptor modulator and is thought to...
Approved
Investigational
Matched Iupac: … cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid
Matched Description: … , disrupting communication between the brain and other parts of the body. ... It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. ... [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients...
Approved
Investigational
Matched Iupac: … cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Matched Description: … has demonstrated safe and effective therapy in both the adult and pediatric population. ... pediatric patients 2 months of age and older. ... Despite being a common and highly contagious bacerial skin infection that affects millions of children …
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours...
Approved
Investigational
Matched Description: … [A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces ... investigated in other cancers, such as colon cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans. It results from a gain-of-function missense mutation in FGFR3 that results in a dramatic suppression of bone growth, both in volume and in length.[A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions, the...
Approved
Investigational
Matched Description: … Achondroplasia is an autosomal dominant genetic disease and the most common cause of dwarfism in humans ... missense mutation in _FGFR3_ that results in a dramatic suppression of bone growth, both in volume and ... [A242273,A242277] Treatment for achondroplasia includes both surgical and pharmacological interventions …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Drugs Affecting Bone Structure and Mineralization ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the...
Approved
Investigational
Matched Description: … It is composed of two heavy chain molecule fragments and 2 light chain fragments. ... binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and ... olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28,...
Approved
Matched Description: … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa ... , as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic …
Matched Categories: … Blood and Blood Forming Organs …
Displaying drugs 2201 - 2225 of 15149 in total